Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

NCT03072160 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

NIH

Sponsor class

Conditions

Medullary Thyroid Cancer (MTC)

Interventions

DRUG: Pembrolizumab

Sponsor

National Cancer Institute (NCI)